Literature DB >> 31345401

Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer.

Ah Ra Jung1, Jong-Lyel Roh2, Jae Seung Kim3, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1.   

Abstract

OBJECTIVES: Diminished skeletal muscle mass (SMM) is a reliable marker of poor survival outcomes in patients with cancer. SMM or body composition is generally assessed at the third lumbar vertebra (L3) by abdominal computed tomography (CT) scans, not routinely evaluated in patients with head and neck squamous cell carcinoma (HNSCC). Therefore, we evaluated the effectiveness of head and neck CT images to assess SMM in patients with HNSCC for predicting their overall survival.
MATERIALS AND METHODS: SMM was assessed in 305 consecutive patients with stage III-IV HNSCC by measuring the cross-sectional area (CSA) at the third lumbar and cervical (C3) vertebrae levels. A formula for predicting the L3 SMM was established using linear regression analysis obtained from C3 CSA and other clinical factors. The actual SMM CSAs measured at L3 level and those obtained from the prediction model were compared using correlation analysis. The predictive power of our formula for estimating overall survival was compared using C-index.
RESULTS: Median SMM CSAs at the L3 and C3 levels were 174.5 cm2 and 56.3 cm2, respectively, and were not strongly correlated (adjusted R2 = 0.421). Prediction model 2 included the strongest predictive factors including sex, age, weight, and C3 SMM CSA, and significantly increased the L3 SMM correlation power (adjusted R2 = 0.721). The C-index of the prediction model was 0.713 (95% confidence interval 0.692-0.747).
CONCLUSIONS: Head and neck CT imaging might be useful to estimate L3 SMM and predict overall survival in HNSCC patients.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cross-sectional area; Head and neck computed tomography; Head and neck squamous cell carcinoma; Prediction; Skeletal muscle mass; Survival

Mesh:

Year:  2019        PMID: 31345401     DOI: 10.1016/j.oraloncology.2019.06.009

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  14 in total

1.  Above and Beyond Age: Prediction of Major Postoperative Adverse Events in Head and Neck Surgery.

Authors:  Marco A Mascarella; Nikesh Muthukrishnan; Farhad Maleki; Marie-Jeanne Kergoat; Keith Richardson; Alex Mlynarek; Veronique-Isabelle Forest; Caroline Reinhold; Diego R Martin; Michael Hier; Nader Sadeghi; Reza Forghani
Journal:  Ann Otol Rhinol Laryngol       Date:  2021-08-20       Impact factor: 1.973

Review 2.  Impact and Treatment of Sarcopenia in Patients Undergoing Radiotherapy: A Multidisciplinary, AMSTAR-2 Compliant Review of Systematic Reviews and Metanalyses.

Authors:  Federica Medici; Alberto Bazzocchi; Milly Buwenge; Alice Zamagni; Gabriella Macchia; Francesco Deodato; Savino Cilla; Pierandrea De Iaco; Anna Myriam Perrone; Lidia Strigari; Stefania Rizzo; Alessio G Morganti
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma.

Authors:  Xin Hua; Jun-Fang Liao; Xin Huang; Han-Ying Huang; Wen Wen; Zhi-Qing Long; Ling Guo; Zhong-Yu Yuan; Huan-Xin Lin
Journal:  Ther Adv Med Oncol       Date:  2020-08-18       Impact factor: 8.168

4.  Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.

Authors:  Xin Hua; Wang-Zhong Li; Xin Huang; Wen Wen; Han-Ying Huang; Zhi-Qing Long; Huan-Xin Lin; Zhong-Yu Yuan; Ling Guo
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

5.  Low skeletal muscle mass assessed directly from the 3rd cervical vertebra can predict pharyngocutaneous fistula risk after total laryngectomy in the male population.

Authors:  Maria Casasayas; Jacinto García-Lorenzo; Beatriz Gómez-Ansón; Victoria Medina; Alejandro Fernández; Miquel Quer; Xavier León
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-19       Impact factor: 2.503

6.  Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: A meta-analysis.

Authors:  Yukinori Takenaka; Norihiko Takemoto; Ryohei Oya; Hidenori Inohara
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

7.  Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer.

Authors:  Brennan Olson; Jared Edwards; Catherine Degnin; Nicole Santucci; Michelle Buncke; Jeffrey Hu; Yiyi Chen; Clifton D Fuller; Mathew Geltzeiler; Aaron J Grossberg; Daniel Clayburgh
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 5.738

Review 8.  Association between skeletal muscle mass and quality of life in adults with cancer: a systematic review and meta-analysis.

Authors:  Lauren Hanna; Kay Nguo; Kate Furness; Judi Porter; Catherine E Huggins
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-02-13       Impact factor: 12.910

9.  Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer.

Authors:  Joon-Kee Yoon; Jeon Yeob Jang; Young-Sil An; Su Jin Lee
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

10.  Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy.

Authors:  Xin Hua; Jun-Fang Liao; Shan Liu; Jun Zhang; Han-Ying Huang; Wen Wen; Zhi-Qing Long; Wen-Wen Zhang; Ling Guo; Huan-Xin Lin
Journal:  Front Nutr       Date:  2020-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.